← All trials
NCT06616883
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2024
- Primary completion
- Nov 14, 2024
- Completion date
- Nov 18, 2024
- First posted
- Sep 27, 2024
- Last posted
- Sep 27, 2024
- Enrollment
- 44
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dong-A PharmaceuticalLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.